Live feed06:55:00·2mPRReleasevia QuantisnowBristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETsByQuantisnow·Wall Street's wire, on your screen.BMY· Bristol-Myers Squibb CompanyHealth Care